{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04665206",
            "orgStudyIdInfo": {
                "id": "VT3989-001"
            },
            "organization": {
                "fullName": "Vivace Therapeutics, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations",
            "officialTitle": "Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (Mutant NF2 or mNF2)",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-to-evaluate-in-patients-with-metastatic-solid-tumors-enriched-for-tumors-with-or-gene-mutations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-03-24",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-05",
            "studyFirstSubmitQcDate": "2020-12-10",
            "studyFirstPostDateStruct": {
                "date": "2020-12-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vivace Therapeutics, Inc",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered once daily in 3- or 4-week cycles in patients with mesothelioma and/or metastatic solid tumors that are resistant or refractory to standard therapy or for which no effective standard therapy is available.",
            "detailedDescription": "Dose escalation will employ a traditional 3 + 3 design to assess safety of VT3989 in patients with refractory metastatic solid tumors or mesothelioma. The 3 + 3 design will be implemented until the MTD or recommended phase 2 dose(s) and schedule(s) are determined. The MTD is defined as the highest dose level at which \\< 33% of patients experience a dose limiting toxicity (DLT) during the first cycle of the study (Cycle 1).\n\nDose Expansion will further evaluate the safety and assess preliminary antitumor activity at the recommended phase 2 dose(s) and schedule(s) with up to 6 cohorts using optimal 2-stage Simon designs. Expansion cohorts 1 and 2 will enroll patients with mesothelioma of any site origin with or without NF2 mutations. Expansion cohort 3 will enroll non-pleural mesothelioma patients. Expansion cohort 4 will enroll solid tumor patients with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor, Adult",
                "Mesothelioma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Part 1 dose escalation: 3 + 3 design Part 2 dose expansion: up to 6 cohorts",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "VT3989 Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "VT3989 dosed orally in 21 or 28 day cycles. Patients will be enrolled into escalating dose levels during the Dose Escalation Phase",
                    "interventionNames": [
                        "Drug: VT3989"
                    ]
                },
                {
                    "label": "Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "VT3989 dosed in 21 or 28 day cycles in patients with refractory metastatic solid tumors or mesothelioma, with or without NF2 mutant tumors.",
                    "interventionNames": [
                        "Drug: VT3989"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VT3989",
                    "description": "25, 50, 100,150 or 200 mg capsules for oral administration.",
                    "armGroupLabels": [
                        "Dose Expansion",
                        "VT3989 Dose Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurrence of Dose Limiting Toxicity",
                    "description": "Incidence of Adverse and Serious Adverse Events",
                    "timeFrame": "over the first 21 days of dosing"
                },
                {
                    "measure": "Occurrence of General Toxicity",
                    "description": "Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations",
                    "timeFrame": "through study completion, an average of 30 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Tumor Response",
                    "description": "Determined by RECIST v1.1 or modified RECIST v1.1",
                    "timeFrame": "through study completion, an average of 30 months"
                },
                {
                    "measure": "Pharmacokinetic Evaluation - Cmax",
                    "description": "Peak plasma concentration of VT3989",
                    "timeFrame": "over first 21 days of dosing"
                },
                {
                    "measure": "Pharmacokinetic Evaluation - Tmax",
                    "description": "Time to reach peak plasma concentration of VT3989",
                    "timeFrame": "over first 21 days of dosing"
                },
                {
                    "measure": "Pharmacokinetic Evaluation - Half-life",
                    "description": "Time required for the plasma concentration of VT3989 to reduce by half after reaching peak",
                    "timeFrame": "over first 21 days of dosing"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Part 1: pathologically diagnosed metastatic solid tumor or mesothelioma that has progressed on or after all approved therapies of known clinical benefit except if the patient refuses or is not a candidate for such therapy;\n* Part 2: In mesothelioma cohorts, pathologically diagnosed advanced malignant mesothelioma with or without NF2 mutations, that has progressed on or after all approved therapies of known clinical benefit except if the patient refuses or is not a candidate for such therapy. In the solid tumor cohort, pathologically diagnosed solid tumor with with clearly inactivating NF2 mutations/alterations or YAP/TAZ gene rearrangements, which have progressed on or after approved therapies of known clinical benefit except if the patient refuses or is not a candidate for such therapy.\n* Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors (solid tumor expansion cohort) or modified RECIST v1.1 for malignant pleural mesothelioma.\n* ECOG: 0-1\n\nExclusion Criteria:\n\n* Active brain metastases or primary CNS (central nervous system) tumors.\n* History of leptomeningeal metastases\n* Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy\n* HIV positive or active Hepatitis B or Hepatitis C\n* Clinically significant cardiovascular disease\n* Additional active malignancy that may confound the assessment of the study endpoints\n* Women who are pregnant or breastfeeding\n* Prior treatment with TEAD inhibitor",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Heather Fritz",
                    "role": "CONTACT",
                    "phone": "650-627-7437",
                    "email": "hfritz@inclin.com"
                },
                {
                    "name": "Neelesh Sharma",
                    "role": "CONTACT",
                    "phone": "732-476-4978",
                    "email": "nsharma@vivacetherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Neleesh Sharma, MD",
                    "affiliation": "Vivace Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Chicago Medical Center",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center-",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Monash Health",
                    "status": "RECRUITING",
                    "city": "Clayton",
                    "state": "Victoria",
                    "zip": "3168",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.91667,
                        "lon": 145.11667
                    }
                },
                {
                    "facility": "Peter MacCullum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Linear Clinical Research",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Heather Fritz",
                            "role": "CONTACT",
                            "phone": "650-627-7437",
                            "email": "hfritz@inclin.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008654",
                    "term": "Mesothelioma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000000236",
                    "term": "Adenoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000018301",
                    "term": "Neoplasms, Mesothelial"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19549",
                    "name": "Neurofibromatoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M12399",
                    "name": "Neurofibromatosis 1",
                    "relevance": "LOW"
                },
                {
                    "id": "M12398",
                    "name": "Neurofibroma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11634",
                    "name": "Mesothelioma",
                    "asFound": "Mesothelioma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2537",
                    "name": "Mesothelioma, Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M18914",
                    "name": "Neurofibromatosis 2",
                    "relevance": "LOW"
                },
                {
                    "id": "M3591",
                    "name": "Adenoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M20445",
                    "name": "Neoplasms, Mesothelial",
                    "relevance": "LOW"
                },
                {
                    "id": "T4096",
                    "name": "Neurofibromatosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4097",
                    "name": "Neurofibromatosis Type 1",
                    "relevance": "LOW"
                },
                {
                    "id": "T4095",
                    "name": "Neurofibroma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3584",
                    "name": "Malignant Mesothelioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4098",
                    "name": "Neurofibromatosis Type 2",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC09",
                    "name": "Ear, Nose, and Throat Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}